{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:00:52Z","timestamp":1787500852296,"version":"build-2736575974"},"reference-count":44,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>Tumor necrosis factor inhibitors (TNFi) are increasingly used in pregnancy but are frequently withheld in the second or third trimesters. We evaluated the maternal and fetal outcomes of women who continued their TNFi throughout pregnancy compared to women who interrupted TNFi during pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>We retrospectively analyzed the outcomes of women seen in clinic with rheumatoid arthritis (RA), psoriatic arthritis, juvenile idiopathic arthritis (JIA), or ankylosing spondylitis, who were exposed to TNFi during pregnancy. We separated pregnancies into 2 groups based on the level of TNFi exposure and compared outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>In Group 1 (TNFi exposure in first trimester only), 11 women had 14 pregnancies and 12 live births. There were 2 first-trimester losses (2\/14, 14%), one in the setting of active RA. Five pregnancies (5\/14, 35.7%) were complicated by a disease flare. Eight patients (8\/12, 66%) flared postpartum. In Group 2 (TNFi exposure throughout pregnancy), 29 women had 32 pregnancies and 34 live births. Three (3\/28, 10.7%) adverse pregnancy outcomes were reported in 2 patients. One patient had a twin pregnancy and delivered at 33 weeks after developing preterm premature rupture of membranes at 32 weeks in the setting of a JIA flare. Her second pregnancy was complicated by active JIA before and throughout gestation, and hemolysis, elevated liver enzyme levels, and low platelet levels (HELLP) syndrome at 39 weeks. Another patient with comorbid antiphospholipid syndrome underwent a cesarean birth at 36 weeks for suspicion of HELLP syndrome. Six (6\/32, 18.7%) postpartum flares occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>Women who discontinued their TNFi during pregnancy had a higher risk of peri- or postpartum flare compared to those who continued their TNFi throughout pregnancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.171152","type":"journal-article","created":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T07:29:46Z","timestamp":1530430186000},"page":"1109-1115","source":"Crossref","is-referenced-by-count":28,"title":["Maternal and Fetal Outcomes in a Cohort of Patients Exposed to Tumor Necrosis Factor Inhibitors throughout Pregnancy"],"prefix":"10.3899","volume":"45","author":[{"given":"Genevi\u00e8ve","family":"Genest","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl A.","family":"Laskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2018,7,1]]},"reference":[{"key":"2018112909385356000_45.8.1109.1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.rdc.2016.12.006","article-title":"Outcomes in children born to women with rheumatic diseases","volume":"43","author":"Vinet","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"2018112909385356000_45.8.1109.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205383"},{"key":"2018112909385356000_45.8.1109.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.24003"},{"key":"2018112909385356000_45.8.1109.4","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.semarthrit.2017.01.002","article-title":"Psoriatic arthritis disease activity during pregnancy and the first year post partum","volume":"46","author":"Polacheck","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2018112909385356000_45.8.1109.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207992"},{"key":"2018112909385356000_45.8.1109.6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.rdc.2016.12.004","article-title":"Fertility, pregnancy, and lactation in rheumatoid arthritis","volume":"43","author":"de Jong","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"2018112909385356000_45.8.1109.7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaut.2016.11.004","article-title":"Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor- \u03b1 use in females with immune mediated diseases; a systematic review and meta-analysis","volume":"76","author":"Komaki","year":"2017","journal-title":"J Autoimmun"},{"key":"2018112909385356000_45.8.1109.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212196"},{"key":"2018112909385356000_45.8.1109.9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-016-8596-x","article-title":"Tumor necrosis factor-alpha and pregnancy: focus on biologics. An updated and comprehensive review","volume":"53","author":"Alijotas-Reig","year":"2017","journal-title":"Clinic Rev Allerg Immunol"},{"key":"2018112909385356000_45.8.1109.10","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1016\/S0016-5085(14)60602-8","article-title":"960 exposure to anti-TNF-alpha therapy in the third trimester of pregnancy is not associated with increased adverse outcomes: results from the PIANO registry","volume":"146","author":"Mahadevan","year":"2014","journal-title":"Gastroenterology"},{"key":"2018112909385356000_45.8.1109.11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2015.08.039","article-title":"Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy","volume":"14","author":"Br\u00f6ms","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2018112909385356000_45.8.1109.12","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309321"},{"key":"2018112909385356000_45.8.1109.13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.12.003"},{"key":"2018112909385356000_45.8.1109.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2010.05.001"},{"key":"2018112909385356000_45.8.1109.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.140822"},{"key":"2018112909385356000_45.8.1109.16","first-page":"S10","article-title":"Serious infections in RA offspring exposed to tumor necrosis factor inhibitors","volume":"68","author":"Vinet","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2018112909385356000_45.8.1109.17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jbspin.2016.03.014","article-title":"Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: a prospective multicentre study","volume":"84","author":"Hoxha","year":"2017","journal-title":"Joint Bone Spine"},{"key":"2018112909385356000_45.8.1109.18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev404"},{"key":"2018112909385356000_45.8.1109.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208840"},{"key":"2018112909385356000_45.8.1109.20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13075-017-1269-1","article-title":"Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients","volume":"19","author":"van den Brandt","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2018112909385356000_45.8.1109.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2012.06.048"},{"key":"2018112909385356000_45.8.1109.22","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/art.39137","article-title":"Brief report: miscarriages in female rheumatoid arthritis patients: associations with serologic findings, disease activity, and antirheumatic drug treatment","volume":"67","author":"Brouwer","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2018112909385356000_45.8.1109.23","doi-asserted-by":"publisher","DOI":"10.1007\/s10995-006-0073-3"},{"key":"2018112909385356000_45.8.1109.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2010.02239.x"},{"key":"2018112909385356000_45.8.1109.25","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140189"},{"key":"2018112909385356000_45.8.1109.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209322"},{"key":"2018112909385356000_45.8.1109.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.05.007"},{"key":"2018112909385356000_45.8.1109.28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1055\/s-0030-1270341","article-title":"Antiphospholipid syndrome and pre-eclampsia","volume":"37","author":"Heilmann","year":"2011","journal-title":"Semin Thromb Hemost"},{"key":"2018112909385356000_45.8.1109.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2012.09.026"},{"key":"2018112909385356000_45.8.1109.30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0412.2011.01152.x"},{"key":"2018112909385356000_45.8.1109.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.placenta.2011.09.015"},{"key":"2018112909385356000_45.8.1109.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2013.08.019"},{"key":"2018112909385356000_45.8.1109.33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/03009742.1998.11720781","article-title":"Obstetrical and neonatal outcome in pregnant patients with rheumatic disease","volume":"107","author":"Skomsvoll","year":"1998","journal-title":"Scand J Rheumatol Suppl"},{"key":"2018112909385356000_45.8.1109.34","doi-asserted-by":"publisher","DOI":"10.1002\/art.21663"},{"key":"2018112909385356000_45.8.1109.35","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000126279.87151.e1"},{"key":"2018112909385356000_45.8.1109.36","first-page":"355","article-title":"Women with inflammatory polyarthritis have babies of lower birth weight","volume":"28","author":"Bowden","year":"2001","journal-title":"J Rheumatol"},{"key":"2018112909385356000_45.8.1109.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra061360"},{"key":"2018112909385356000_45.8.1109.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcibr1404324"},{"key":"2018112909385356000_45.8.1109.39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes428"},{"key":"2018112909385356000_45.8.1109.40","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150592"},{"key":"2018112909385356000_45.8.1109.41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.24095\/hpcdp.35.1.04","article-title":"Congenital anomalies in Canada 2013: a perinatal health surveillance report by the Public Health Agency of Canada\u2019s Canadian Perinatal Surveillance System","volume":"35","author":"Irvine","year":"2015","journal-title":"Health Promot Chronic Dis Prev Can"},{"key":"2018112909385356000_45.8.1109.42","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12642"},{"key":"2018112909385356000_45.8.1109.43","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/pds.4261","article-title":"Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use","volume":"26","author":"Carman","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2018112909385356000_45.8.1109.44","doi-asserted-by":"publisher","DOI":"10.1002\/art.24914"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.171152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T14:28:34Z","timestamp":1543501714000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.171152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,1]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,1]]},"published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.3899\/jrheum.171152"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.171152","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,1]]}}}